In an effort to broaden the immune response induced by the RTS,S/AS02A,vaccine, we have evaluated the immunogenicity of the RTS,S antigen when combined with MSP142 and with AMA1, antigens derived from the asexual blood stage.
Further work is required to ascertain whether ease of use and compliance may be important factors in the outcomes associated with malariachemoprophylaxis.
If a mosquito-transmitted brain tumor virus could be identified, development of a brain tumor vaccine might be possible.
In conclusion, measuring antigen-specific T cells is more meaningful than NK cells in these vaccination regimens.
This study examined the effect of different housing and household characteristics on malaria risk among 98 case and 185 control children in the semi-urban area of Nouna, Burkina Faso.
In this study, the P. vivax merozoite surface protein 10 (MSP-10) was expressed as a recombinant protein in Escherichia coli and purified by affinity chromatography.
Antigen Pf332, a megadalton protein has been shown to be associated with the membrane of infected erythrocytes. Detailed functional studies on the antigen have remained hampered by the cross-reactive nature of antibodies generated to Pf332. Pf332-C231, identified in the C-terminal region of Pf332 was cloned and antibodies against the C231 fragment were shown to react with intact Pf332 antigen by both immunofluorescence and immunoblotting analyses. Antibodies to C231 inhibited in vitro Plasmodium falciparum growth efficiently.
A classic way of delaying drug resistance is to use an alternative when possible. We tested the malaria treatment Argemone mexicana decoction (AM), a validated self-prepared traditional medicine made with one widely available plant and safe across wide dose variations. In an attempt to reflect the real situation in the home-based management of malaria in a remote Malian village, 301 patients with presumed uncomplicated malaria (median age 5 years) were randomly assigned to receive AM or artesunate-amodiaquine [artemisinin combination therapy (ACT)] as first-line treatment.
The WHO Initiative for Vaccine Research (IVR) Malaria Vaccine Advisory Committee (MALVAC) provides advice to WHO on priorities in malaria vaccine research and development (R&D).
The findings not only indicate that artemisinins do not require Hb-FeII or heme-FeII for promotion of antimalarial activity, but are also important in relation to the therapy of severe/complicated or cerebral malaria.